Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
Status:
Completed
Trial end date:
2021-03-12
Target enrollment:
Participant gender:
Summary
In this study, the investigators propose to administer clazakizumab to patients with
life-threatening Coronavirus Disease 2019 (COVID-19) infection manifest by pulmonary failure
and a clinical picture consistent with a cytokine storm syndrome. This is a single-center
randomized, double-blind, placebo-controlled trial in which 30 patients will be enrolled and
randomly assigned in a 1:1 ratio to two study arms and receive clazakizumab at a dose of 25
mg or placebo.